HLB Group said Wednesday it will hold the “2026 HLB Forum” for two days starting May 12 at Sofitel Ambassador Seoul, under the theme “DNA of Success, Continuous Innovation; Unstoppable Challenge.”
Now in its fourth year, the forum will bring together the group’s biotech affiliates along with pharmaceutical, biotech and investment experts from South Korea and abroad. The event will review global industry trends and assess progress and next steps for key pipelines, the company said.
HLB said it will share updates on new modality development alongside broader global biotech trends. A main focus will be development and commercialization strategy for next-generation oncology programs following its liver cancer and bile duct cancer drug candidates that are in the approval stage. Affiliates will also present pipeline progress and follow-up plans, with discussions aimed at refining specific approaches.
The forum will also cover major industry issues including the regulatory environment, disease-specific development strategies, artificial intelligence-based drug development, investment trends and examples of entering the U.S. market.
HLB said it plans to use the forum to strengthen cooperation among affiliates and speed commercialization of its pipeline. The group recently hired global pharmaceutical and biotech business development expert Yang Eun-young as president to bolster global commercialization capabilities across its affiliates, it said.
“This forum is an opportunity to make our future strategy more concrete based on the drug development experience and global network the group has built,” Nam Gyeong-suk, managing director in HLB Group’s Bio Strategy Planning Team, said in a statement. “We will continue strengthening our R&D and commercialization capabilities so each affiliate’s pipeline can translate into meaningful results in the global market.”
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.